Research Article
Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
Table 1
Baseline characteristics of the 18 systemic lupus erythematosus patients and their main refractory and active involvement.
| ||||||||||||||||||||||||||||||||||||||
All the data correspond to (%) with the exemption of those marked with *. *Median IQR (interquartile range). **Proteinuria (higher than 0.5 g/day), casts (erythrocytes, hemoglobin, granular, tubular, or mixed), hematuria, and pyuria. ***Leukopenia (less than 4.000 cells/mm3), thrombocytopenia (less than 100.000 cells/mm3), and hemolytic anemia. |